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S U M M A R Y
Despite the relevance of extensively drug-resistant tuberculosis (XDR-TB) to global TB control efforts,
case reports on patients achieving cure are scarce. The case of a patient who was treated for more than
3 years as a multidrug-resistant TB (MDR-TB) case, and who was diagnosed retrospectively with XDR-TB,
is presented herein. Soon after the initiation of a capreomycin and para-aminosalicylic acid-based
regimen, the patient converted and treatment was completed successfully.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Extensively drug-resistant tuberculosis (XDR-TB) is a sub-
category of multidrug-resistant (MDR) Mycobacterium tuberculosis
strains.1 MDR-TB strains are resistant to the ﬁrst-line drugs
isoniazid and rifampicin, while XDR-TB has additional resistance to
certain second-line drugs, viz. a ﬂuoroquinolone as well as any of
the second-line injectable drugs amikacin/kanamycin, or capreo-
mycin.1 In 2010 the World Health Organization (WHO) estimated
that 5.4% of all MDR-TB cases globally were XDR-TB.1 Treatment
outcomes among XDR-TB cases are typiﬁed by high death rates,
low conversion rates, and low successful treatment outcome rates.
The treatment of XDR-TB places a substantial burden on TB
control programmes.2 Patients are hospitalized for long periods of
time; default rates are high and treatment durations are as long as
36 months in some cases. The few drugs available for treatment are
costly, highly toxic, and of low efﬁcacy.3 Management requires a
skilled clinical team and regimens need to be individualized.
Treatment is based on drug sensitivity testing, the results of which
take several weeks to become available, and not all results are
reliable. Due to the slow response to treatment, XDR-TB cases are
likely to remain smear-positive for longer, presenting an increased
infection control risk. Hospitalization requires adequately* Corresponding author at: Private bag X385, Pretoria, 0001, South Africa
E-mail address: vdwalt@mrc.ac.za (M. van der Walt).
http://dx.doi.org/10.1016/j.ijid.2015.09.020
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).designed wards, and cases with smear-positive sputa should be
discharged only under carefully considered circumstances.
Although XDR-TB shows encouraging treatment outcomes in
certain settings,4 outcomes in Africa remain poor. Individualized
case reports of patients achieving cure are scarce. The case of a
patient with XDR-TB who achieved early culture conversion and
eventual cure once an effective regimen was prescribed, is
described below. Optimal management of this case was impaired
by challenges in performing drug susceptibility testing (Figure 1).
2. Case report
2.1. TB history and management
In May 2003, the patient – a female aged 44 years – presented to
her local clinic in the Western Cape Province of South Africa with
symptoms of coughing and weight loss. She tested HIV-negative.
She smoked and used alcohol intermittently during the initial
years of treatment, but subsequently stopped. The patient was
treated under the DOTS-Plus programme.5
Following diagnosis of TB with a positive smear, the patient was
started on ﬁrst-line treatment (Figure 1). Sputum was taken and
tested against isoniazid, rifampicin, and ethambutol. The results
became available in July 2003 and showed the patient to have
MDR-TB. She was referred to an MDR in-patient facility, some
300 km away from her home, in line with the DOTS-Plus protocol.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Treatment history and bacteriology results.
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MDR-TB treatment regimen in July 2003 (Figure 1) and was treated
according to the DOTS-Plus guidelines.5 This consisted of a4–6-month intensive phase of pyrazinamide, ethambutol, ethion-
amide, oﬂoxacin, and amikacin/kanamycin. Pyrazinamide and
amikacin/kanamycin were then stopped, and the remaining drugs
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resistance to ethambutol in this woman, an individualized regimen
was started in November 2003: clofazimine and terizidone were
added and pyrazinamide was continued. Amikacin/kanamycin was
given for a total of 8 months.
On admission, the patient weighed 47 kg (having put on 5 kg
since diagnosis). After 2 months of inpatient care, the subject was
still sputum smear-positive and culture-positive. She had, howev-
er, gained a further 3 kg and was discharged to continue ambulatory
treatment at a clinic close to her home. She was followed-up on a
2-monthly basis by a clinician-based outreach team.
The patient was declared a treatment failure in October
2005 after 24 months of treatment, and terizidone was stopped.
The other three drugs – ethionamide, pyrazinamide, and oﬂoxacin
– were continued while sensitivity testing to second-line drugs
was attempted.
When the patient’s weight dropped to 46 kg in April 2008, she
was readmitted to the MDR-TB inpatient facility where a
capreomycin and para-aminosalicylic acid-based regimen was
initiated. These drugs have low efﬁcacy against TB and only
became available for the treatment of XDR-TB in South Africa in
2007.3 Clarithromycin and amoxicillin–clavulanate, also drugs
without proven efﬁcacy against TB, were used to bolster the
regimen and terizidone was reintroduced.
The patient converted to sputum culture-negative within 71 days.
In February 2011 she was declared cured and treatment was stopped.
She was subsequently followed up by the clinical outreach team until
the end of April 2013 with no recurrence of the TB.
As early as July 2005 it was determined that this patient was not
a candidate for surgery due to bilateral disease. In October 2011,
after a massive haemoptysis, she was seen by a pulmonologist who
reported that her lung functions were poor. A six-minute walk test
showed the pre-stress test at 92% and post-stress test at 77%. She
also had extensive bronchiectasis and impaired respiratory
reserves. At this time a Mycobacterium abscessus (non-tuberculous
Mycobacterium (NTM)) was cultured from her sputum. She did not
attend any more of her scheduled appointments possibly due to
the distance in travelling to the specialist centre.
2.2. Sputum results
As per guidelines, monthly sputa were collected for microscopy
and culture. These exhibited a low bacterial load on microscopy,
although cultures remained positive and contaminated, resulting
in very few follow-up sensitivity results available to guide
treatment. Under the DOTS-Plus programme, sputa were collected
and batched for second-line drug sensitivity testing.5 The results
were not reported back for clinical management partly due to the
lack of drugs for the implementation of individualized regimens.
In 2006, with the advent of and deﬁning of XDR-TB, the DOTS-
Plus sputum results were investigated retrospectively to deter-
mine the occurrence of XDR-TB. The present patient’s July
2004 sputum was used for sensitivity testing, demonstrating
resistance to the following second-line drugs: amikacin/kanamy-
cin, oﬂoxacin, and ethionamide. This information was only added
to her ﬁle in 2007, but due to inherent challenges in obtaining
second-line drug susceptibility testing, this result was not
conﬁrmed until September 2007 (Figure 1). The ongoing isolation
of NTM from her sputum was deemed to be of no clinical relevance
and did not warrant further investigations or treatment.
2.3. Drug side effects
Side effects were monitored passively,5 and the patient
experienced few side effects. She started complaining of skin
hyperpigmentation at 4 months after the start of clofazimine, andthis was eventually stopped after 8 months when the patient
complained of unacceptable levels of skin discolouration. She
experienced minor side effects due to the para-aminosalicylic acid
and admitted to the treating physician that she only took it in the
morning as the night dose made her ‘‘feel bloated’’. In March 2009,
both clarithromycin and pyrazinamide were stopped due to
arthralgia. Despite experiencing these side effects, she was by
her own account adherent with the community-based treatment.
3. Discussion
The case study presented here demonstrates the importance of
the timely performance of second-line drug sensitivity testing to
identify patients who are not responding well to MDR-TB
treatment. When resistance to second-line drugs is the cause of
a poor response to treatment, changing the regimen to one that is
effective is imperative. The drugs to which the patient demon-
strates resistance should be withdrawn and replaced with at least
two new drugs to which the patient has not previously been
exposed.
The conventional, culture-based procedure for drug sensitivity
testing when hampered by ongoing contamination, as seen in the
present case, interferes with the monitoring of treatment and
prevents clinicians from adjusting treatment should it be required.
The early initiation of treatment with appropriate drugs is
crucial. In retrospect, with the knowledge that this patient had XDR-
TB, she had essentially received 4 years of ineffective treatment. It is
therefore remarkable how well the patient responded to the new
capreomycin and para-aminosalicylic acid-based regimen, show-
ing culture conversion in just over 2 months. It may well be that the
addition of clofazimine, clarithromycin, and amoxicillin–clavula-
nate contributed to this positive response on treatment. Even
though the patient achieved treatment cure, she was left with a
destroyed left lung, which could have been prevented.
The patient was granted early discharge from inpatient care
when treatment was ﬁrst started in 2003. This deviation from the
infection control policy for MDR-TB was based on the decision of
her clinical team. Factors such as bed availability, accessibility to
the clinic for daily monitoring, the patient’s clinical condition, and
the infection risk to the family were all considered carefully.
Finally, this case report reminds us that the implementation of
high quality directly observed therapy programmes is crucial to
ensure proper treatment of all TB patients, in order to prevent the
emergence of MDR and XDR M. tuberculosis strains.
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